These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34298761)

  • 1. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Patel B; Saba NF
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
    Alorabi M; Shonka NA; Ganti AK
    Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.
    Shaib W; Kono S; Saba N
    J Oncol; 2012; 2012():521215. PubMed ID: 22778735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new horizon in the treatment of head and neck cancer - anti-epidermal growth factor receptor monoclonal antibodies as novel options].
    Tahara M; Fujii M
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2489-507. PubMed ID: 23235168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
    Kono SA; Haigentz M; Yom SS; Saba N
    Chemother Res Pract; 2012; 2012():901320. PubMed ID: 23056941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Argiris A; Harrington KJ; Tahara M; Schulten J; Chomette P; Ferreira Castro A; Licitra L
    Front Oncol; 2017; 7():72. PubMed ID: 28536670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab in the treatment of head and neck cancer.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
    von der Grün J; Rödel F; Brandts C; Fokas E; Guckenberger M; Rödel C; Balermpas P
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on cetuximab in squamous cell carcinoma of the head and neck.
    Frampton JE
    BioDrugs; 2011 Apr; 25(2):129-33. PubMed ID: 21443275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).
    Echarri MJ; Lopez-Martin A; Hitt R
    Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.